LS1034Homo sapiens (Human)Cancer cell line

Also known as: LS-1034, LS 1034, LS103A

🤖 AI SummaryBased on 16 publications

Quick Overview

LS1034 is a colorectal cancer cell line used in research for understanding tumor biology and drug responses.

Detailed Summary

LS1034 is a colorectal cancer cell line derived from a human tumor. It is widely used in cancer research to study the molecular mechanisms of tumor progression and drug sensitivity. This cell line has been characterized for its genetic and epigenetic features, including mutations in key oncogenes and tumor suppressor genes. Research on LS1034 has contributed to understanding the role of specific genetic alterations in cancer development and therapeutic responses. The cell line is also utilized in studies related to microsatellite instability and the identification of potential therapeutic targets. Its use in preclinical models helps in evaluating the efficacy of anticancer drugs and in developing personalized treatment strategies.
Generated on 6/16/2025

Basic Information

Database IDCVCL_1382
SpeciesHomo sapiens (Human)
Tissue SourceCecum[UBERON:UBERON_0001153]

Donor Information

Age54
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseCecum adenocarcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeATCC
Source IDACH-000252_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Gly245Ser (c.733G>A)UnspecifiedSomatic mutation acquired during proliferationPubMed=28445466
MutationSimpleKRASp.Ala146Thr (c.436G>A)UnspecifiedIn 50% of the readsPubMed=27004849
MutationSimpleAPCp.Glu1309Aspfs*4 (c.3927_3931delAAAGA)Homozygous-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D13S317
12
D16S539
9,11
D18S51
20
D19S433
13,15
D21S11
29,30
D2S1338
17,25
D3S1358
15,18
D5S818
12,13
D7S820
8,12
D8S1179
13
FGA
20
Penta D
11,13
Penta E
5,13
TH01
7
TPOX
9,11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Mol. Cancer 16:116.1-116.16(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Clin. Cancer Res. 21:3695-3704(2015).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Epigenetic and genetic features of 24 colon cancer cell lines.";

Hektoen M., Lind G.E., Lothe R.A.

Oncogenesis 2:e71.1-e71.8(2013).

Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.

Grade M., Gaedcke J.

Radiother. Oncol. 108:451-457(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Cancer Res. 70:5901-5911(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

Recurrent KRAS codon 146 mutations in human colorectal cancer.";

Yuen S.T., Leung S.Y., Stratton M.R., Futreal P.A.

Cancer Biol. Ther. 5:928-932(2006).

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Hamelin R.

Oncogene 20:5025-5032(2001).

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Wolf E., Gabius H.-J.

J. Cancer Res. Clin. Oncol. 127:375-386(2001).

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Hamelin R.

Cancer Res. 57:300-303(1997).

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Thomas G., Hamelin R.

Oncogene 13:2727-2730(1996).

Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.

Suardet L., Li C., Little J.B.

Int. J. Cancer 68:126-131(1996).

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).

Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.

Eliason J.F., Odartchenko N.

Cancer Res. 52:3705-3712(1992).

Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1.

Lorenzoni M., Givel J.-C., Odartchenko N.

Eur. J. Cancer 28A:1894-1899(1992).